Constellation Brands, Inc. (NYSE: STZ) — America’s Best Beer Franchise, Re-Rated to a No-Growth Staple With Its Brewery in Mexico

Independent equity research. Report date: 2026-06-26.

This article is independent fundamental research. With the single, clearly-labeled exception of the “Author’s Take” block immediately below, it carries no buy/sell recommendation and no price target — the body discusses valuation only as embedded expectations and scenarios.

⚡ Author’s Take

This block is the author’s own subjective opinion. It is general information, not investment advice. The analysis that follows takes no position and carries no price target.

Verdict: HOLD / accumulate-on-weakness — a high-conviction-quality, medium-conviction-thesis call. Constellation owns the single best growth franchise in American beer — Modelo Especial (the #1-selling beer in the United States by dollars), Corona, and the two fastest-growing major imports, Pacifico and Victoria — a business earning a ~39% segment operating margin that has compounded volume for fifteen years while the rest of US beer shrank. The market has repriced this franchise from a flawless compounder (~26x earnings, ~$258, early 2024) to a faintly-distressed staple (~12.4x comparable earnings, ~$146 today). STZ now trades in the 16th percentile of its own decade-long P/E range and the 5th percentile on price-to-sales, at ~11x EV/EBITDA and a ~7% free-cash-flow yield, with a 2.8% dividend covered at a ~35% payout. My fair-value zone is roughly $165–$200 (≈13.5–16x normalized ~$12 comparable EPS / ≈11.5–13x ~$3.2B EBITDA), with a credible bull path toward the low-$200s and a genuine bear floor near $115–125. The asymmetry from $146 — ~15–20% downside vs. ~15–40% base-case upside plus the yield — is favorable but not a fat pitch, because the bear case here is not imaginary.

The framing is fallen-angel / contrarian-value, not falling knife — and the distinction is evidence-based. The tape was a one-way street (−14.5%/yr over three years, a −63% lifetime peak drawdown), but the factor model now reads a defensive staple (beta 0.40, factor-similar to Kraft Heinz, Campbell’s and Brown-Forman) with a +10.6% six-month bounce off the November-2025 low — a name being abandoned, not liquidated. What separates this from its cousin Brown-Forman (which I like slightly better on the same de-rating logic) are two overhangs that are uniquely Constellation’s and that I do not think are fully cyclical. First, ~50% of STZ’s beer volume is bought by Hispanic consumers, and 2025’s immigration-enforcement climate produced a demand chill that demographics and politics — not the beer — control. Second, every drop of Constellation’s beer is brewed in Mexico, which makes the company a standing hostage to US tariff policy in a way no other large US staple is; a durable Mexican beer tariff outside USMCA’s protection would permanently compress the franchise’s best-in-class margin. Layer on a genuinely awful capital-allocation scar (the ~$4B Canopy cannabis investment, essentially written to zero), GLP-1/moderation pressure on the whole category, and pro-cyclical buybacks executed at $200+, and the trough multiple is earned, not a free lunch. I think the market is modestly too bearish on the beer franchise’s durable earning power and appropriately worried about the tail risks — so this is “buy the franchise at a staple multiple and get paid to wait,” not a catalyst trade. Conviction: medium. The single fact that flips me decisively bullish: two consecutive quarters of positive beer depletion growth with the Mexican tariff question resolved inside USMCA. The single fact that flips me bearish: an enacted, durable beer-specific tariff, or a third year of beer-volume declines that converts “cyclical air-pocket” into “the demographic engine has stalled.”

The tag: The best beer franchise in America, marked down to a no-growth staple — priced for stagnation, hostage to a border.

📈 Stock Price Action — Five-Year Event Map

Constellation has round-tripped a full cycle. From a COVID-recovery base in the low-$200s through 2021–2022, the stock rode the Modelo-takes-#1 narrative to an all-time high near $258 (adjusted close, March 2024), then de-rated almost without interruption to a five-year low of $126 (November 2025) as beer volumes stalled, the wine business was written down and sold, tariff fears mounted, and Berkshire Hathaway built and then abandoned a position. It now sits at $146.30 (2026-06-26) — roughly 43% below its 2024 high, near the bottom decile of its own ten-year valuation range, with a 52-week range of ~$126–$171. The move is overwhelmingly a multiple event: comparable EPS only fell from ~$12.0 (FY23) to $11.82 (FY26), while the P/E compressed from the mid-20s to ~12x.

Cycle narrative. (1) 2021–22 was a holding pattern: a strong beer business whose equity value was masked by Canopy losses and serial wine write-downs. (2) The 2022–24 leg up was the Modelo coronation — when Bud Light’s 2023 boycott handed Modelo Especial the #1 dollar-share crown in US beer, the franchise’s growth story crystallized and the multiple expanded to ~26x. (3)–(5) The 2024–25 collapse was a pile-up of distinct, verifiable shocks: decelerating depletions, the wine impairment-and-divestiture, the Section-232 aluminum tariffs and the threat of a 25% Mexican import tariff (existential for a 100%-Mexico brewer), an immigration-enforcement climate that chilled the core Hispanic consumer, and a cascade of guidance cuts that withdrew the multi-year algorithm. (6) The 2025–26 bounce is stabilization, not re-acceleration — sequential Q4 improvement, a “solid” March, and a clean leadership handoff to Nick Fink — set against the symbolically negative Q1-2026 Berkshire exit. The price move is fact; the attributed causes are interpretation. No price target or recommendation is implied here — the opportunity judgment lives in the Author’s Take above.

1. Executive Summary

Constellation Brands is, in its core, one of the highest-quality consumer-staples franchises in the US market — and for the first time since the mid-2010s it trades at a price that treats it as ordinary. After a deliberate decade-long transformation, Constellation is now ~91% a US imported-beer company: in FY2026 (year ended 2026-02-28) Beer was $8,315M of $9,139M total net sales, with the remaining ~9% a deliberately-shrunk, premiumized Wine & Spirits portfolio. The beer business is exceptional — it holds the exclusive US rights to the Modelo, Corona, Pacifico and Victoria families; Modelo Especial is the single best-selling beer in America by dollar sales; and the segment earns a ~39% operating margin, roughly double a typical domestic brewer. Management grew beer from ~280M cases to over 400M cases in seven years, gaining US share every year while the overall beer category was flat-to-down.

The investment situation is a violent de-rating of a quality franchise into a genuine cyclical-and-structural fog. From a March-2024 high near $258, the stock has fallen ~43% to ~$146, erasing roughly $20B of market value while comparable EPS barely moved (FY2023 ~$12.0 → FY2026 $11.82). This is almost entirely multiple compression: the P/E has collapsed from the mid-20s to ~12.4x comparable earnings, EV/EBITDA from ~16x to ~11x, and the stock sits in the 16th percentile of its own ten-year P/E range and the 5th percentile on price-to-sales. It yields 2.8% (covered at a ~35% payout) and throws off a ~7% free-cash-flow yield.

The core debate is cyclical vs. structural, with a tariff tail. The bull case: the demand air-pocket is macro and consumer-confidence driven (a “more selective” shopper, a temporary Hispanic-demographic chill), Modelo and Pacifico are still gaining share, beer exited FY2026 with sequential improvement and a “solid” March, and a ~39%-margin franchise generating ~$1.8B of free cash should not trade like a melting staple. The bear case: per-capita alcohol consumption is in secular decline (GLP-1 drugs, generational moderation, the cancer-risk narrative), the franchise is uniquely exposed to a Hispanic consumer base (~50% of beer volume) buffeted by immigration policy, the wine business has already proven a melting asset, capital allocation has a catastrophic recent scar (Canopy), and — the structural sword over the whole thesis — 100% of the beer is brewed in Mexico, making margins hostage to US trade policy.

The financials show a real, high-return franchise wrapped in noisy GAAP. Reported net income swings wildly because of non-operating items — the FY2025 GAAP loss reflects a $2,740.7M wine goodwill impairment (written to zero) and the multi-year Canopy write-down; comparable earnings are the right lens. On that lens, beer margins are best-in-class, ROIC on the operating business is high-teens-plus, and free cash flow is robust. The balance sheet carries ~$10.5B net debt (3.2x EBITDA, ~9x interest coverage — investment grade), modestly de-levered from FY2023. Capital allocation is a study in contrasts: a competent, growing dividend and a real $4B buyback authorization, undercut by ~$4B of value destroyed in the Canopy cannabis bet and a history of buying stock pro-cyclically above $200. A genuine governance positive bookends the period — the 2022 elimination of the Sands family’s super-voting Class B stock — and a new CEO, Nicholas Fink (ex-Fortune Brands Innovations), took over in April 2026.

At ~$146, the market is underwriting a no-growth-to-slowly-declining franchise with a permanent tariff discount. This memo argues those embedded expectations look modestly too bearish on the beer franchise’s durable earning power and appropriately cautious on the structural and tariff tails. It takes no position; it lays out what must be true for each side.

2. Business Overview

Constellation Brands, founded in 1945 and headquartered in Rochester (offices in Victor), New York, is the largest producer and marketer of imported beer in the United States and, after a multi-year reshaping, a focused premium beer house with a small high-end wine and spirits tail. The fiscal year ends the last day of February; FY2026 closed 2026-02-28 and the 10-K was filed 2026-04-22. The company reports two operating segments — Beer and Wine and Spirits — plus Corporate.

What it sells (FY2026 net sales, $9,139.0M).

• Beer — $8,315.2M (91% of net sales). Constellation holds the exclusive, perpetual right to import, market and sell the Modelo and Corona portfolios in all 50 US states (a right acquired from Anheuser-Busch InBev in the 2013 Grupo Modelo divestiture forced by US antitrust regulators). The portfolio:
  • Modelo Brand Family — Modelo Especial (the #1-selling beer overall in the US by dollar sales), Modelo Chelada, Modelo Negra, Modelo Oro, Modelo Noche Especial, Modelo Spiked Aguas Frescas.
  • Corona Brand Family — Corona Extra (the #2 import / #5 overall US beer), Corona Familiar, Corona Light, Corona Premier, Corona Non-Alcoholic, Corona Sunbrew.
  • Pacifico and the Victoria Brand Family (Victoria, Vicky Chamoy) — the two fastest-growing major imported beer brands in the US.
  • All beer is brewed in Mexico at company breweries in Nava and Obregón, with a third major facility in Veracruz expected to begin production around the middle of FY2027.
• Wine and Spirits — $823.8M (9%). A deliberately-shrunk, premiumized portfolio after the FY2025–FY2026 divestitures: Wine $700.4M (Kim Crawford, Meiomi, The Prisoner, Robert Mondavi Winery, SIMI, Ruffino, Schrader, Sea Smoke) and Spirits $123.4M (High West whiskey, Casa Noble tequila, Mi Campo, Nelson’s Green Brier). The company sold its mainstream wine brands to The Wine Group (closed June 2025) and SVEDKA vodka (closed January 2025), exiting the value end to focus on higher-margin, higher-end labels.

How it makes money. Constellation is a brand-owner, brewer and importer. In beer it brews in Mexico, imports under USMCA, and sells through a US three-tier distribution system (one beer wholesaler network represents ~25% of consolidated net sales). The economics are extraordinary for a brewer: gross margin ~52% company-wide, and a beer segment operating margin of ~39–40% — a function of premium pricing, scale in a single growth portfolio, and low-cost Mexican production. Marketing runs ~9–9.5% of beer sales. Wine & Spirits sells through a separate distributor network (one wholesaler carries a large share of branded W&S sales) and now targets a low-20s% operating margin.

Recurring vs. non-recurring. Beer is a high-frequency, brand-loyal repeat consumable — revenue is highly recurring at the brand level, though exposed to discretionary cycles, weather/seasonality (summer-weighted), and shipment-vs-depletion timing with distributors. It is not subscription-like. The single most important demand characteristic: Constellation’s beer skews heavily to Hispanic consumers (management estimates roughly half of beer volume), a demographic that is younger and faster-growing than the US average but also more sensitive to economic and immigration-policy shocks.

Verdict: A focused, premium, brand-led imported-beer franchise with an iconic, legally-protected portfolio and the best growth and margin profile in US beer, plus a small higher-end W&S tail. The model is high-margin and recurring, but concentrated by category (beer ~91%), by geography of production (100% Mexico), and by consumer base (~50% Hispanic) — three concentrations that are the source of both the franchise’s quality and its present discount.

3. Industry Dynamics

Structure of US beer. The US beer market is a consolidated, mature oligopoly in structural volume decline at the headline level, masking a sharp internal divergence. Total US beer volume has been flat-to-down for a decade as consumers trade out of mainstream domestic lager. Within that shrinking pie, the “high end” (imports + craft + above-premium) has taken persistent share, and imports — overwhelmingly Mexican — have been the single best-performing segment. Anheuser-Busch InBev (Bud Light, Budweiser, Michelob Ultra) and Molson Coors (Coors Light, Miller Lite) dominate domestic premium and are in secular volume decline; Constellation owns the import growth engine; Heineken, Diageo (Guinness) and a long craft tail fill the rest. The competitive set that matters for STZ is Mexican imports (where it has no domestic peer of scale), Michelob Ultra (the one growing domestic mainstream brand, ABI’s), and the broader “share-of-throat” battle against spirits, RTDs, hard seltzer and cannabis.

Profit pools and pricing. Beer is a scale business with meaningful brand pricing power at the premium end. Constellation has taken ~1–2% annual price for years while gaining volume — a rare combination — because Modelo/Corona occupy an aspirational-yet-affordable position with deep Hispanic-community loyalty and broadening “general-market” appeal. The category’s structural attractiveness is bifurcated: domestic mainstream is a melting, low-margin commodity; the high-end import niche STZ dominates has been genuinely good. The risk is that the whole category faces a demand ceiling.

The secular demand question. Three forces pressure all alcohol: (i) generational moderation — Gen Z drinks materially less than prior cohorts at the same age; (ii) GLP-1 weight-loss drugs, which clinical and survey data suggest reduce alcohol consumption among users; and (iii) a tightening cultural/regulatory climate (the January 2025 US Surgeon General advisory linking alcohol to cancer; dry-January’s normalization; non-alcoholic alternatives). IWSR and most sell-side work judge the current downturn “more cyclical than structural,” but the structural overhang is real and is the reason the entire beverage-alcohol cohort — Brown-Forman, Diageo, Boston Beer, Molson Coors — has de-rated together.

Regulation and the three-tier system. US alcohol is sold through a state-mandated three-tier system (producer/importer → distributor → retailer) that creates entrenched distributor relationships (a moat-like barrier, but also a source of shipment-timing volatility and distributor-destocking risk). Excise taxes, state alcohol-control regimes, and — critically for STZ — trade and tariff policy are the binding regulatory variables. Constellation’s 100%-Mexico production base means US-Mexico trade relations are an industry-structural factor for STZ specifically: USMCA currently shields beer, but Section-232 aluminum tariffs already raise can costs, and the 2025 threat of a 25% Mexican import tariff was an existential scenario that the stock partially priced.

Capital cycle (Marathon lens). The high-end import niche attracted capital — Constellation poured billions into Mexican brewing capacity (Nava, Obregón, now Veracruz; ~$700M+ capex in FY2026, ~$800M guided FY2027). This is the classic late-cycle signature: heavy capacity additions into a demand slowdown create near-term fixed-cost-absorption headwinds (explicitly flagged for FY2027 beer margins). The discipline question — whether STZ throttles capex as volume stalls — is live; management says it is managing the build “modularly” and delaying/avoiding spend.

Verdict: a structurally attractive niche inside a structurally challenged category. Constellation sits in the one part of US beer that has reliably grown, with real pricing power and a distribution moat — but the category’s secular demand ceiling, and STZ’s unique tariff exposure, mean the industry tailwind is narrowing. Net: good niche, questionable category, binary trade-policy overlay.

4. Competitive Position

The moat — and it is a real one. Constellation’s competitive advantage in beer is a genuine, multi-layered moat that surfaces directly in financials (a ~39% operating margin and 15 years of share gains):

1. Irreplaceable brand-portfolio + exclusive perpetual import rights (intangible asset). The crown jewel is the perpetual, exclusive US right to Modelo and Corona — brands Constellation does not own globally but controls absolutely in the US market, courtesy of the 2013 antitrust-forced divestiture. These are aspirational, century-old brands with deep authenticity among Hispanic consumers and growing general-market pull. In Greenwald’s taxonomy this is a demand-side advantage (customer captivity via brand) reinforced by a unique, non-replicable contractual asset — a competitor cannot buy or build “the #1 beer in America.”
2. Distribution scale and shelf dominance (economies of scale + distribution). As the import growth leader, STZ commands disproportionate distributor attention, shelf space and cold-box placement — a self-reinforcing advantage as retailers allocate space to the brands that turn. Six of the top-15 share-gaining beer brands in the US are Constellation’s.
3. Low-cost Mexican production at scale (cost advantage — but the double-edged one). The Mexican brewery footprint is a structural cost advantage and the source of the tariff vulnerability. It underwrites the margin today and threatens it under adverse trade policy.

Pressure-testing. Is the moat durable? On the brand and distribution dimensions, yes — there is no domestic substitute for the Modelo/Corona franchise, switching costs for distributors and retailers are real, and the share-gain record is the proof. The two genuine cracks: (i) the moat protects share within beer, not against the category’s demand ceiling or against spirits/RTD/cannabis substitution; and (ii) the cost-advantage leg is policy-contingent in a way few moats are — a tariff converts the franchise’s greatest strength into a margin liability overnight. Network effects are not a meaningful factor here.

Versus competitors. Against Anheuser-Busch InBev and Molson Coors, Constellation is the structural winner — it has the growth, the margin, and the demographic tailwind they lack; ABI’s Michelob Ultra is the one domestic brand competing for the same “premium active” occasion. Against spirits (Brown-Forman, Diageo) and RTDs, beer is ceding some “share of throat,” but Modelo/Pacifico are gaining within their lane. Constellation’s beer margins (~39%) exceed those of essentially every scaled beverage-alcohol peer.

Verdict: a durable advantage in its niche — one of the best brand-and-distribution moats in US consumer staples — but a moat with two structural asterisks (category demand ceiling; policy-contingent cost base). The advantage is real and financially visible; it is not unconditional.

5. Growth History and Forward Opportunities

History. Constellation’s beer business is one of the great volume-growth stories in US staples: from ~280M cases when Newlands era began to over 400M cases today, with US share gains every year. Reported company net sales grew from $8.34B (FY2020) to a peak $10.21B (FY2025) before falling to $9.14B (FY2026) — but that FY2026 drop is divestiture-driven, not core erosion: $711.2M of the decline was the sale of mainstream wine/SVEDKA, with beer down a comparatively modest 2.6% ($8,539.8M → $8,315.2M) on a shipment-volume decline (−$323.0M) partly offset by pricing (+$128.2M). Beer has been the engine throughout; wine and spirits has been a shrinking, lower-quality drag now largely jettisoned.

The recent stall. The crux of the bear case is that beer growth — the entire thesis — stalled in FY2025–FY2026. Depletions decelerated, then turned negative for three quarters of FY2026 before a Q4 sequential improvement. Management attributes this to a “more selective” consumer and, candidly, to a Hispanic-consumer pullback driven by 2025’s economic caution and immigration-enforcement climate (it tracks demand by ZIP-code Hispanic-density quintiles; all quintiles improved sequentially in Q4, with California regaining a full share point). This is the single most important growth datum: it is genuinely ambiguous between cyclical (macro/policy that mean-reverts) and structural (a demographic engine losing torque).

Forward opportunities.

• Pacifico — exploding, geographically broadening from the West Coast nationally (the same playbook that built Modelo); management’s designated next growth driver.
• Victoria — bringing in a younger (21–25) Hispanic consumer, more than doubled in recent years; a cohort-renewal asset.
• Modelo headroom — still under-distributed in much of the country relative to its #1 status; continued general-market penetration.
• High-end light beer (Corona Premier/Modelo Oro repositioning), non-alcoholic (Corona NA, Modelo Chelada NA, Sunbrew), and innovation/limited offerings (Modelo Noche Especial, Chelada Suprema) addressing moderation/flavor trends.
• World Cup 2026 marketing tentpole — heavy first-half FY2027 brand investment.
• Wine & Spirits stabilization — a smaller, premium portfolio (Kim Crawford, Mi Campo growing) targeting a return to low-20s margins as distributor destocking ends.

FY2027 guidance frames the near term as flat: beer net sales −1% to +1%, enterprise comparable EPS $11.20–$11.90 (flat-to-down), and the multi-year FY2028 outlook withdrawn — an explicit admission of low visibility.

Verdict: historically high-quality growth (organic, branded, share-gaining, priced), now stalled and of newly-uncertain quality. The forward opportunity set is real and credible (Pacifico/Victoria/Modelo headroom), but the company itself will only guide to flat for FY2027 and has pulled its longer algorithm. Growth is the swing variable of the entire thesis, and it is currently unproven.

6. Financial Quality

Read comparable, not GAAP. Constellation’s reported net income is among the noisiest in staples because of recurring large non-operating items. GAAP diluted EPS was $9.61 in FY2026, but the multi-year GAAP series includes net losses in FY2020, FY2022, FY2023 and FY2025 — none of which reflect the operating business. The FY2025 GAAP loss (−$0.45/sh) is driven by a $2,740.7M wine goodwill impairment (carrying value written to zero) plus a $57.0M trademark impairment; FY2020/FY2022/FY2023 losses are driven by Canopy equity-method write-downs. Comparable diluted EPS strips these (plus acquisition amortization, restructuring, and the Canopy mark): $11.82 in FY2026 (FY2025 $13.78; Q4 FY2026 $1.90, −28% YoY). The comparable line is the correct earning-power anchor.

Margins — best-in-class and stable. Company gross margin ~52% (51.6% FY2026, down ~50bps on beer cost inflation, partly offset by mix from divesting low-margin wine). Beer segment operating margin runs ~39–40% — roughly double a domestic brewer — guided down to 37–38% for FY2027 on (i) Veracruz brewery fixed-cost absorption ahead of volume, (ii) higher marketing (~9.5% of sales, World Cup) and (iii) lower incentive-comp reversal, partly offset by 1–2% pricing, cost savings, and aluminum-tariff relief. The margin compression is real but specific and arguably temporary (capacity-timing). EBITDA margin ~36% (FY2026 EBITDA $3,281.8M).

Returns on capital. On a GAAP basis ROIC is ~10.8% and ROE ~12.9% (ROIC.ai, FY2026), depressed by the goodwill/intangible-heavy balance sheet and prior impairments. On the operating business (beer-dominated, comparable earnings), returns are high-teens-plus; the beer segment in isolation earns ~39% operating margins on a modest invested-capital base. The honest read: excellent unit economics in beer, dragged down at the consolidated level by acquisition goodwill and the Canopy/wine write-downs. Note tangible book is essentially zero/negative — goodwill ($5.23B) + other intangibles ($2.53B) ≈ $7.77B against total equity of $8.08B — so book-value metrics are not meaningful; this is a brand-and-brewery business, not an asset-value one.

Cash flow. FCF is robust and consistent: FY2026 operating cash flow $2,669M less capex $875M ≈ $1,794M FCF (~$10.2/share), a ~7% free-cash-flow yield at the current price. Cash conversion is high (OCF/comparable NI > 1.3x). The one caveat: capex is elevated (~$800M FY2027) for brewery expansion into a volume slowdown — a Marathon-style warning that FCF could be temporarily over-stated relative to a normalized, lower-capex state, or that capex is being spent ahead of demand that may not materialize on schedule.

Balance sheet. Net debt ~$10.47B (total debt $11.20B, cash $102M), 3.2x EBITDA net leverage, ~9x EBITDA/interest coverage — comfortably investment grade (BBB+/Baa-area). Net debt has declined from ~$12.3B (FY2023), a modest, deliberate de-lever. The debt is well-laddered senior notes (recent $500M issues May-2025 and Oct-2025). Liquidity is adequate; the current ratio is ~1.08.

Verdict: economics that clearly improve with scale in beer, but a consolidated picture muddied by goodwill and a history of write-downs. The operating franchise is high-margin, high-return and cash-generative; the reported financials require normalization; the balance sheet is sound. Quality of the business is high; quality of the reported earnings requires the comparable lens.

7. Capital Allocation

Capital allocation is the most contested part of the Constellation story, and the honest verdict is mixed — competent on the routine, scarred on the big swing.

The Canopy scar. Between 2017 and 2018 Constellation invested ~$4 billion for a ~38% stake in Canopy Growth, the Canadian cannabis company, on a thesis that legal cannabis would be the next great consumer-beverage category and that STZ could lead it. It was a near-total loss. The equity-method investment was written down repeatedly (the carrying value was already ~$266M by mid-2023 after earlier impairments, then cut to $142.7M with a further $123.5M impairment); in April 2024 the common shares were converted into non-voting, non-participating Exchangeable Shares (restructured into “Canopy USA” to wall off cannabis exposure), which were then written down to $21.2M (a $76.1M FY2025 impairment). Constellation now owns 26.3M Exchangeable Shares worth ~$21M — a >99% loss on a $4B bet. This is the single worst capital-allocation decision in the company’s modern history and it appropriately weighs on management’s credibility for any future “adjacency” ambition.

Buybacks — large but pro-cyclical. Constellation is a serial repurchaser. The $2.0B (2021) authorization was fully used by FY2025; the Board authorized a fresh $4.0B program in April 2025, of which $2,977.2M remained as of April 2026 (so ~$1B repurchased in FY2026, plus 641,481 shares post-FYE at $153.86). The pattern is the familiar staples flaw: the company bought heavily at $200+ in FY2022–FY2024 and is buying less aggressively now near multi-year lows — value-destructive timing, the inverse of what a disciplined allocator would do. Share count has fallen from ~194M (FY2021) to ~173M (FY2026), so the program is real and accretive, but executed at poor average prices.

Dividend — competent and growing. The quarterly dividend was raised to $1.03/share Class A (April 2026), ~$4.12 annualized, a ~2.8% yield at ~35% of comparable EPS — well-covered and consistently grown (from ~$2.97 in FY2020). Total shareholder returns were ~$900M+ in FY2026; ~$700M of dividends guided for FY2027.

M&A and divestitures — late-cycle reshaping. The recent record is disposal-heavy and broadly sensible: exiting mainstream wine (The Wine Group, 2025), SVEDKA (2025), and earlier the Nobilo/lower-end labels, while bolting on small premium brands (Sea Smoke, Austin Cocktails, My Favorite Neighbor). The strategic logic — concentrate on high-margin beer and premium W&S — is correct; the execution has crystallized large impairments on assets bought in earlier, less-disciplined eras.

Capex. ~$700M+ in FY2026, ~$800M guided FY2027, almost entirely Mexican brewery capacity (Veracruz). This is the right kind of spend if beer volume re-accelerates and the wrong kind if it does not — and it is being deployed into a demonstrated volume slowdown. Management’s “modular, delay-or-avoid” framing is the correct instinct; execution is the test.

Governance positive — the 2022 dual-class elimination. In June 2022 Constellation eliminated the Sands family’s super-voting Class B stock, moving to a cleaner one-share-one-vote structure (the family retains Class A and board-nomination rights). This was a genuine governance upgrade for outside shareholders, removing an entrenched control overhang — and stands in contrast to peers (e.g., Brown-Forman) that retain family voting control.

Incentives. Compensation is the standard staples mix (comparable EPS growth, net sales, comparable operating margin, relative TSR); notably it lacks an explicit return-on-invested-capital governor — a relevant gap given the Canopy history. Insider behavior over 2025–2026 is the usual pattern: routine equity grants (code A) to directors and the CEO and small discretionary sales (code S), with zero open-market purchases — no conviction-buying signal at the lows.

Verdict: competent stewardship of a great franchise, with one catastrophic adjacency bet (Canopy), pro-cyclical buyback timing, and no ROIC discipline in pay. Has management allocated capital intelligently? On balance, below the quality of the underlying business — adequate, not admirable.

8. Changes and Headwinds — Last Two Years

Strategic / portfolio. (i) Wine & Spirits divestitures — sold mainstream wine to The Wine Group (closed June 2025) and SVEDKA (closed January 2025), shrinking W&S to a ~9%, premium-only tail and recognizing the $2.74B wine goodwill impairment. (ii) Canopy restructured into “Canopy USA” and converted to Exchangeable Shares (April 2024), effectively closing the cannabis chapter at a near-total loss. (iii) Capacity build — continued Mexican brewery expansion (Veracruz online ~mid-FY2027).

Leadership. Nicholas Fink (former CEO of Fortune Brands Innovations; a Constellation board member for five years) became CEO on April 13, 2026, succeeding Bill Newlands (CEO seven years, who built the Modelo franchise and moves to strategic-adviser). CFO Garth Hankinson remains. A clean, telegraphed succession — but a new hand on the wheel at a delicate moment, and a “show-me” on capital allocation and strategy.

Macro / consumer headwinds. (i) A “more selective,” value-seeking consumer pressured the whole beverage-alcohol category for most of FY2026. (ii) A Hispanic-consumer pullback — economic caution plus 2025’s immigration-enforcement climate chilled the demographic that buys ~half of STZ’s beer — the most company-specific demand shock, showing sequential improvement by Q4. (iii) GLP-1 / moderation / cancer-narrative secular overhang on all alcohol.

Trade / tariffs — the defining new risk. (i) Section-232 aluminum tariffs raised can-input costs (FY2027 brings some relief, per management). (ii) The 2025 threat of a 25% tariff on Mexican imports was, for a 100%-Mexico brewer, an existential scenario that drove much of the 2025 de-rating; USMCA has so far shielded beer, but the risk is unresolved and policy-contingent. (iii) Retaliatory actions abroad — Canada (STZ’s largest W&S export market) banned US wine and spirits from shelves, directly hitting the W&S segment.

Financial / market. Repeated FY2026 guidance cuts; withdrawal of the FY2028 algorithm; the stock’s ~43% drawdown; and the symbolically negative Berkshire Hathaway exit in Q1-2026 (after building a ~$1.2B stake in late 2024/early 2025) — the marquee value buyer arrived and then left within ~15 months.

Verdict: net thesis-weakening over two years, but with the seeds of stabilization. The franchise’s quality is intact and W&S has been rationalized, but the period introduced a genuine demand stall, a uniquely dangerous tariff exposure, a leadership change, and the loss of its highest-profile shareholder. The Q4/March sequential improvement is the only clear positive. The two years left the business cleaner but the thesis riskier.

9. Risk Analysis (Risk Matrix)

Overall: The risk profile is dominated by two high-impact, medium-likelihood structural/policy risks (Mexican tariff; structural volume) plus the demographic exposure — a meaningfully riskier set than a typical defensive staple, which is precisely why the multiple has compressed. The probability of catastrophic loss is very low; the probability of a multi-year “value-trap” stagnation is non-trivial.

10. Valuation (Embedded Expectations)

Where it trades. At $146.30 (2026-06-26), with ~172.8M shares, equity value is ~$25.3B; adding ~$10.47B net debt and ~$0.30B minority interest gives an enterprise value of ~$36.0B. Against FY2026 figures:

The stock is in the bottom decile of its own ten-year valuation range on a composite basis and the 5th percentile on price-to-sales — the cheapest it has been as a public company on most measures, on a beer franchise whose comparable earnings are essentially flat versus three years ago.

Peer context. Constellation now trades roughly in line with — or below — beverage-alcohol peers despite a superior margin and growth profile: Brown-Forman (~11.5x EV/EBITDA, also bottom-decile own-history), Diageo and Molson Coors (high-single-digit to low-double-digit EV/EBITDA), versus high-quality non-alcoholic staples (Coca-Cola, PepsiCo, Monster) at meaningfully richer multiples. STZ’s ~39% beer margin is best-in-cohort; its multiple is bottom-of-cohort. The market is paying nothing for the quality premium the franchise historically commanded.

Embedded-expectations analysis — what must be true at $146? A ~12.4x comparable P/E with a 2.8% yield implies the market is pricing low-single-digit-to-zero terminal earnings growth — i.e., a no-growth defensive staple with a permanent risk discount. To justify $146 as fair, you must believe: (i) beer volume is structurally capped (the demographic/GLP-1/moderation bears are right), (ii) the ~39% margin carries a durable tariff/cost discount, and/or (iii) capital allocation continues to leak value. Notably, the price is not discounting outright terminal decline — that scenario (≈8–9x EBITDA, mid-$110s–$120s) is roughly the November-2025 low. Nor is it paying for any return to mid-single-digit beer growth, which the company delivered for a decade.

Scenario analysis (illustrative; not price targets):

• Bear (~$115–125): Beer volume declines ~MSD structurally; a Mexican tariff (or its threat) compresses beer margin toward low-30s; comparable EPS drifts to ~$10–10.50; the multiple stays ~10–11x EV/EBITDA. This is roughly the late-2025 trough — the market has already visited it.
• Base (~$165–200): Beer stabilizes at roughly flat-to-LSD volume with continued pricing; FY2027 EPS ~$11.50, recovering toward ~$12.50–13 by FY2029 as Pacifico/Victoria scale and Veracruz absorption normalizes; the multiple re-rates modestly to ~13.5–16x comparable EPS / ~11.5–13x EV/EBITDA as the tariff fog clears. ~$165–200.
• Bull (~$210–240): Beer re-accelerates to MSD volume (Hispanic demand normalizes, Pacifico inflects national); margins recover to ~40%; comparable EPS compounds to ~$14–15 by FY2030; the multiple re-rates to ~16–18x as the “structural decline” narrative is disproven. Low-$200s+.

No price target. No recommendation. The embedded expectations look modestly too pessimistic on the beer franchise’s durable earning power, and appropriately cautious on the tariff/structural tails — the value question turns entirely on cyclical-vs-structural and on Mexican trade policy.

11. Variant Perception

Consensus belief. The Street is split-to-constructive: price targets cluster $157–$185 (UBS $175 Buy, Needham $185 Buy, TD Cowen $174 Buy, JPM $169 Neutral, Jefferies $157 Hold) — i.e., most analysts see upside but a meaningful cohort is sidelined on visibility. The prevailing narrative: “great beer franchise, real near-term demand and tariff fog, wait for depletion inflection.” Consensus comparable EPS hugs the FY2027 guide ($11.20–$11.90).

Strongest bull case. This is the best franchise in US beer trading at a no-growth staple multiple. Modelo is #1 in America, Pacifico and Victoria are the fastest-growing imports, the segment earns ~39% margins, and the company throws off ~$1.8B of free cash at a ~7% yield while paying a covered, growing 2.8% dividend. The FY2026 demand stall is macro/policy-driven (a cautious consumer, an immigration chill) and already reversing (Q4 sequential improvement, “solid” March, California regaining share). The category downturn is “more cyclical than structural” (IWSR). Buy a decade-long compounder at a trough multiple with the demographic tailwind (Hispanic population growth) intact and a fixable wine drag now jettisoned.

Strongest bear case. The growth engine has structurally stalled. US alcohol faces a secular per-capita ceiling (GLP-1, generational moderation, cancer narrative); STZ’s specific Hispanic-consumer dependence is a vulnerability, not a tailwind, in a hostile immigration climate; and — the killer — 100% Mexican production makes the franchise’s margin hostage to one man’s trade policy. Three years of flat comparable EPS, pro-cyclical buybacks, a $4B cannabis incineration, capex ramping into a volume slowdown, and the smartest value investor on earth (Berkshire) buying and then selling within 15 months. A ~12x multiple on a no-growth, policy-exposed business may be correct, not cheap.

The 3–5 assumptions that matter most:

1. Is beer volume cyclical or structural? (The whole thesis.) Falsified bearishly by a third consecutive year of negative depletions; falsified bullishly by two consecutive quarters of positive depletions.
2. Mexican tariff outcome. Falsified bearishly by an enacted, durable beer-specific tariff outside USMCA; confirmed bullishly by USMCA continuing to shield beer.
3. Hispanic-consumer normalization. Falsified bearishly by continued ZIP-quintile deterioration; confirmed by the Q4-2026 sequential trend persisting.
4. Margin durability. Falsified by beer margin failing to recover from the 37–38% FY2027 trough back toward 40%; confirmed by post-Veracruz absorption normalizing margins.
5. Capital-allocation discipline under Fink. Falsified by a new value-destructive adjacency or continued $150+ buybacks into stagnation; confirmed by ROIC discipline and counter-cyclical repurchase.

Factor-positioning read (Momentum/factor model). The tape and factor loadings corroborate “abandoned value,” not “falling knife”: beta 0.40, factor-similar to defensive staples (Kraft Heinz, Campbell’s, Brown-Forman, Flowers) — the market now prices STZ as a no-growth staple, which is itself the variant-perception opportunity if the beer franchise is more durable than a Kraft Heinz. Risk-adjusted returns are brutal over 3–5 years (−14.5%/yr, −6.5%/yr) but the most recent six months bounced +10.6% off the November-2025 low, and the name carries no momentum/growth loadings to unwind. The factor model says: a defensive value name where consensus has given up on growth — offsides if growth merely stabilizes.

Where consensus may be wrong: The market has collapsed STZ’s multiple to staple-average while its margin and (potential) growth remain best-in-cohort. If beer volume merely stabilizes near flat and the tariff fog clears within USMCA, the quality premium re-rates. The variant view is not “growth re-accelerates” (too uncertain) — it is “the franchise is more durable than a 12x no-growth multiple implies, and the tail risks, while real, are being priced as base cases.”

12. Fact vs. Interpretation Table

13. Open Questions

1. Cyclical or structural? Will beer depletions return to positive growth in FY2027, or is the demographic/GLP-1/moderation ceiling real? (The single decisive question.)
2. Mexican tariff: Does USMCA continue to shield beer, or does a durable beer-specific tariff materialize — and at what rate? What is STZ’s realistic mitigation (pricing, sourcing, can localization)?
3. Hispanic demand: Is the 2025 pullback a transient immigration-policy chill or a longer demand impairment? How durable is the Q4-2026 sequential improvement?
4. Capital allocation under Fink: Will the new CEO impose ROIC discipline, buy back counter-cyclically, and avoid another adjacency misadventure?
5. Capex discipline: Is the ~$800M FY2027 brewery spend (Veracruz) appropriately sized to demand, or building capacity into a stall?
6. Wine & Spirits floor: Has the premium W&S portfolio found a stable ~low-20s-margin base, or does it keep eroding?
7. Berkshire’s reasoning: Was the exit a portfolio/valuation call or a structural-thesis rejection? (Unknowable, but informative.)

14. What Must Be True

Bull case — what must be true (and its falsification test):

• US beer volume is structurally durable and STZ’s share gains continue (Pacifico/Victoria scale, Modelo penetrates). Falsification: a third consecutive fiscal year of negative beer depletions.
• USMCA continues to shield Mexican beer, or any tariff is modest/temporary and offset by pricing. Falsification: an enacted, durable beer-specific tariff outside USMCA.
• The Hispanic-consumer pullback normalizes; the Q4-2026 sequential improvement persists. Falsification: ZIP-quintile demand deteriorates again through FY2027.
• Margins recover from the FY2027 trough back toward 40% as Veracruz absorption normalizes. Falsification: beer operating margin fails to recover above ~38% by FY2029.
• New CEO Fink allocates capital with discipline. Falsification: a new value-destructive adjacency acquisition or continued buybacks at $150+ into stagnation.

Bear case — what must be true (and its falsification test):

• Per-capita alcohol demand is in secular decline and STZ’s beer franchise cannot grow volume durably. Falsification: two consecutive quarters of positive beer depletion growth.
• The Mexican production base is a permanent, policy-driven margin liability. Falsification: trade policy stabilizes with beer protected for a multi-year horizon.
• The ~$4B Canopy loss and pro-cyclical buybacks reflect a structurally poor allocator that the new CEO won’t fix. Falsification: a clear pivot to ROIC-linked pay and counter-cyclical capital return.
• At ~12x a no-growth, policy-exposed business, the multiple is correct, not cheap. Falsification: the multiple re-rates above ~15x comparable EPS as growth stabilizes — proving the trough was a mispricing.

15. Source Appendix

See the source appendix below for the full, dated source list. Primary sources: Constellation Brands FY2026 Form 10-K (filed 2026-04-22, SEC EDGAR CIK 0000016918); Q4 FY2026 earnings call transcript (2026-04-09); FY2026 Q4 earnings release (8-K, 2026-04-08); the trailing 60-month SEC corpus (10-K/10-Q/8-K/DEF 14A/Form 4). Quantitative data: aggregated fundamental data (ROIC.ai) (statements, ratios, enterprise value); own-history valuation percentiles percentiles and price history; FactorsToday factor model. All third-party aggregated data reconciled to filings; management commentary treated as hypothesis and validated against filings and external data.

APPENDIX A — Standard Diligence Questionnaire — Constellation Brands, Inc. (NYSE: STZ)

Supplemental to the research memo (not counted toward the memo length standard). Answers are grounded in the research log and labeled Fact / Interpretation / Assumption where it matters. As-of date 2026-06-26; figures FY2026 (year ended 2026-02-28) unless noted.

General

What thoughtful questions have other investors asked about this company? The dominant investor debates: (1) Is the beer-volume slowdown cyclical or structural (GLP-1, generational moderation, demographics)? (2) What is the Mexican tariff exposure and mitigation, given 100% of beer is brewed in Mexico? (3) How durable is the Hispanic-consumer demand base (~50% of beer volume) amid an immigration-enforcement climate? (4) Will the ~39% beer margin recover from the FY2027 trough? (5) Can a serial mis-allocator (Canopy) be trusted with $3B of buyback authorization and ~$800M/yr of capex? (6) Why did Berkshire buy and then exit within ~15 months? (7) Is comparable EPS (the right lens) sustainable when GAAP is so noisy?

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Interpretation: Below trend, not a low. Comparable EPS fell from ~$13.78 (FY2025) to $11.82 (FY2026) and is guided flat-to-down ($11.20–$11.90) for FY2027 — a demand-and-margin air-pocket (Veracruz fixed-cost absorption, cautious consumer), not a cyclical trough in the commodity sense. The multiple is at a decade low; earnings are merely soft.

Driven by external environment or internal actions? Both. External: cautious consumer, Hispanic-demand chill, tariff/cost inflation. Internal: deliberate wine divestitures (reduced sales base), capacity build (margin drag), pricing discipline (+1–2%).

How stable are revenues? Beer is highly recurring and brand-loyal but exposed to discretionary spending, weather/seasonality (summer-weighted), and distributor shipment-vs-depletion timing. ~91% beer concentration raises single-category dependence.

Outlook for products/services? Interpretation: Beer flat-to-modestly-growing near term (FY2027 net sales −1% to +1%), with credible medium-term drivers (Pacifico, Victoria, Modelo headroom, NA/innovation). W&S stabilizing at a smaller, premium base targeting low-20s margins.

How big will this market be — growing, shrinking, domestic or international? US beer overall is flat-to-shrinking; the high-end import niche STZ dominates has grown for 15 years and is supported by Hispanic population growth — but faces a secular per-capita-alcohol ceiling. Predominantly a US business (beer is US-only rights; W&S has modest international).

Business Quality & Competitive Moat

Is the industry getting more or less competitive? Interpretation: Within imports, STZ has no domestic peer of scale; the broader battle (vs. spirits/RTD/cannabis for “share of throat,” and vs. Michelob Ultra in premium) is intensifying at the category margin. Net: stable-to-slightly-more competitive.

How profitable is the business (ROIC, ROE)? GAAP ROIC ~10.8%, ROE ~12.9% (depressed by goodwill/impairments). On the operating beer business, returns are high-teens-plus; beer segment operating margin ~39%.

How profitable is the industry — competitors, barriers to entry? Bifurcated: domestic mainstream is low-margin and declining; the premium-import niche is high-margin. Barriers: irreplaceable brands, exclusive perpetual import rights, distribution scale, and the three-tier system. High for the niche STZ occupies.

Can the business be easily understood? Yes — sell premium Mexican beer in the US at high margins, plus a small premium wine/spirits tail. The complications are GAAP noise (impairments/Canopy) and the tariff overlay.

Can it be undermined by foreign low-cost labor? No — the moat is brand/distribution, and production is already in low-cost Mexico (which is the tariff vulnerability, not a labor-arbitrage threat).

Do brands matter? Decisively. Modelo/Corona/Pacifico are the entire moat — aspirational, century-old, deeply loyal among Hispanic consumers.

Nature of competition / customers’ switching costs? Consumer switching costs are low (brand loyalty is the only retention), but distributor/retailer relationships and shelf dominance create real B2B switching friction and a self-reinforcing share advantage.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? The exclusive perpetual Modelo/Corona US import rights and brand equity are worth vastly more than carried; the Mexican brewery network (net PP&E ~$9.1B) is a real hard asset. Conversely, tangible book is ~zero (goodwill $5.23B + intangibles $2.53B ≈ equity).

Off-balance-sheet liabilities? Operating/finance leases (~$634M capital leases), purchase commitments (grapes, agave, aluminum, gas — hedged ~75–100% for FY2027), and the residual Canopy/Exchangeable-Share exposure (~$21M, immaterial). No alarming hidden liabilities.

How conservative is the accounting? Interpretation: The company has been aggressive then corrective historically (large goodwill carried on wine/Canopy, then written down hard). Going forward, post-impairment, the balance sheet is cleaner. Comparable adjustments are reasonable but exclude recurring-ish items (amortization, restructuring) — scrutinize.

How CapEx-hungry is the business? Moderately — ~$700–800M/yr (~8–9% of sales), almost entirely Mexican brewery capacity. Elevated relative to a mature staple because of the growth-capacity build; a swing factor for FCF.

Capital Allocation & Management

How much FCF, and how is it used? ~$1.79B FY2026 FCF. Uses: ~$700M dividends, ~$900M+ total returns (incl. buybacks), debt reduction, and capex. Philosophy: grow sales/margins/cash, maintain target leverage and ~30% payout, return excess via buybacks.

Significant acquisitions recently? Net divestitures — sold mainstream wine (The Wine Group, 2025) and SVEDKA (2025); small premium bolt-ons (Sea Smoke). The defining historical M&A is the catastrophic ~$4B Canopy cannabis investment (~total loss).

Buying back shares? Yes — $4.0B authorization (April 2025), ~$3.0B remaining (April 2026); ~$924M FY2026. Share count down ~194M→173M since FY2021. Critique: pro-cyclical (heavy at $200+, lighter at lows).

Issuing shares to insiders? Routine equity grants only (SBC ~$68M, modest). No abusive dilution.

Compensation policy? Standard staples metrics (comparable EPS, net sales, comparable operating margin, relative TSR). Gap: no explicit ROIC hurdle — relevant given Canopy.

Motivations of management? Interpretation: New CEO Nicholas Fink (ex-Fortune Brands Innovations, board member 5 yrs) took over April 2026; CFO Hankinson continues. Dual-class eliminated 2022 (Sands family gave up super-voting) — a governance positive. Insiders: routine grants/sales, zero open-market buys — no conviction signal.

Valuation & Market Data

ADR, MLP, or K-1 issuer? No — a US Delaware C-corp, NYSE-listed Class A common (STZ). Standard 1099 treatment.

Dividend policy? Quarterly $1.03/share Class A ($4.12/yr), ~2.8% yield, ~35% payout of comparable EPS, consistently grown; ~$700M FY2027 guided.

How profitable is the business? Very, in beer (~39% segment operating margin, ~52% gross); consolidated muddied by goodwill/impairments.

Is net income diverging from cash from operations? GAAP NI is understated vs cash in impairment years (FY2025 GAAP loss vs $3.15B OCF); comparable NI tracks cash well (OCF/comparable NI ~1.3x). Use comparable.

Risks & Downside

What factors would cause the stock to decline? An enacted durable Mexican beer tariff; a third year of negative beer depletions (structural confirmation); continued Hispanic-demand deterioration; margin failing to recover; a new capital-misallocation event; broad alcohol-category de-rating.

Risk of catastrophic loss? Low. Profitable, cash-generative, investment-grade, irreplaceable brands. The realistic downside is multi-year stagnation/value-trap (~$115–125), not impairment.

Chance of a total loss? Negligible absent a simultaneous extreme tariff + demand collapse — not a credible scenario for an IG, cash-generative franchise.

Recent News & Events

Has the business environment changed recently? Yes — tariff regime (Section-232 aluminum; Mexican-import threat), Hispanic-demand chill, leadership change (Fink, April 2026), Berkshire exit (Q1-2026), W&S divestitures completed. Q4-2026/March showed sequential beer improvement.

Significant acquisitions / accounting changes? Divestitures (wine, SVEDKA); $2.74B FY2025 wine goodwill impairment; Canopy converted to Exchangeable Shares (2024). No adverse accounting-policy changes flagged.

Recent changes — new markets, facilities, management? New Veracruz brewery (online ~mid-FY2027); new CEO; smaller, premiumized W&S portfolio; World Cup 2026 marketing push.

APPENDIX B — Source Appendix — Constellation Brands, Inc. (NYSE: STZ)

Report date 2026-06-26. Primary sources first. All third-party aggregated data reconciled to filings; management commentary treated as hypothesis. SEC EDGAR CIK 0000016918; CUSIP 21036P108; ISIN US21036P1084.

Primary — SEC filings (EDGAR)

1. Form 10-K, FY2026 (year ended 2026-02-28), filed 2026-04-22 — stz-20260228.htm. Segment net sales (Beer $8,315.2M / Wine & Spirits $823.8M); $2,740.7M FY2025 wine goodwill impairment + $57.0M trademark impairment; Canopy Exchangeable Shares ($21.2M, $76.1M FY2025 impairment); buyback authorizations ($4.0B April-2025, $2,977.2M remaining 2026-04-17); dividend ($1.03/qtr Class A declared 2026-04-08); tariff risk factors (Section 232); Sands-family reclassification (June 2022).
2. Form 10-K, FY2022–FY2025 — stz-20220228 … stz-20250228 — multi-year financials, Canopy impairment history, dual-class elimination.
3. Form 8-K, FY2026 Q4 earnings, 2026-04-08 — stzex991_022826 (Exhibit 99.1) — comparable EPS $11.82 FY2026 (Q4 $1.90); FY2027 comparable EPS guidance $11.20–$11.90; FY2028 outlook withdrawn; dividend raise.
4. Form 8-K corpus (96 saved; earnings, guidance updates, authorizations, exec/board changes).
5. DEF 14A proxy statements — compensation metrics (comparable EPS, net sales, comparable operating margin, relative TSR; no ROIC hurdle); Sands-family nomination rights.
6. Form 4 corpus (2025–2026) — directors/CEO grants (code A) and small executive sales (code S); zero open-market purchases (code P).
7. S-4 / 425 (2022) — Reclassification Agreement eliminating Class B super-voting stock.
8. Full trailing 60-month SEC corpus reviewed (since 2021-06-01).

Primary — Management commentary

9. Q4 FY2026 earnings call transcript, 2026-04-09 (ROIC.ai) — CEO transition (Newlands → Fink, eff. 2026-04-13); FY2027 beer guide −1% to +1%; beer margin 37–38% (Veracruz absorption, marketing 9.5% of sales, aluminum-tariff relief); W&S low-20s medium-term target; Hispanic ZIP-quintile sequential improvement; Pacifico/Victoria growth; hedging (fuel ~100%, aluminum ~90%, peso ~80%).

Quantitative data sources

10. aggregated fundamental data (ROIC.ai) — income statement, balance sheet, cash flow, profitability/credit ratios, enterprise value, valuation multiples, per-share data, company profile (FY2020–FY2026). Net leverage 3.2x; FCF ~$1.79B; ROIC ~10.8%; EV ~$39B (FY-end) / ~$36B (live at $146.30).
11. own-history valuation percentiles (2026-06-25) — composite percentile 15.9th; P/E 16.6th, P/B 25.9th, P/S 5.1th (own ~decade history). BVPS $46.54.
12. price history — five-year price arc; ATH ~$258.61 (Mar-2024), low $125.98 (Nov-2025), $146.30 (2026-06-26).
13. FactorsToday factor model — beta 0.40; market 0.54; Consumer-Staples loading; leaderboard (y3 −14.5%/yr, y5 −6.5%/yr, m6 +10.6%, lifetime maxDD −62.9%); factor-similar peers KHC/CPB/Brown-Forman/Flowers.

Industry / news

14. financial news aggregators (2026) — analyst PT cluster ($157–$185); Berkshire Q1-2026 exit coverage; Q1-FY2027 earnings preview.
15. IWSR, Circana, Beer Marketers Insights, Beer Institute, NABCA — industry/market-position data (cited in 10-K).
16. CNBC (2026-04-08) — “Constellation Brands withdraws 2028 guidance”; press releases (cbrands.com / globenewswire) — FY2026 outlook updates.
17. Peer cross-read: Brown-Forman public filings and disclosures — beverage-alcohol industry structure, the structural-vs-cyclical debate, and GLP-1/moderation framing (same de-rating cohort).

Notes on reliability

• GAAP net income is distorted by recurring large non-operating items (impairments, Canopy); comparable EPS is the earning-power anchor.
• ROIC.ai book_val_per_sh ($77.40) is garbled; AZI BVPS $46.54 reconciles to equity/share and is used. ROIC EV is struck near FY-end price; EV re-derived at the live $146.30.
• Berkshire build/exit is 13F-based and news-confirmed (exact quarters to verify against the underlying 13F).
• Hispanic-volume share (~50%) is a management estimate, not an audited disclosure.